You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text

    SBC: GRAYRAIN, LLC            Topic: NCATS

    PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Genome Editing Therapy for Usher Syndrome Type 3

    SBC: GENETOBE INC            Topic: NEI

    PROJECT SUMMARY/ABSTRACTUsher syndrome type 3A (USH3A), an autosomal recessive disorder, is characterized by progressive loss of hearing and vision due to a clarin-1 (CLRN1) gene mutation. A person with type 3 Usher syndrome will usually require cochlea implants by mid- to late adulthood and classified as being legally blind. The management of the chronic, progressive, severe vision loss (retiniti ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Precision Medicine for Alcohol-Associated Liver Disease

    SBC: GENETOBE INC            Topic: 150

    ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Structure-based computational engineering of saCas9 PAM requirement

    SBC: ATGC Inc.            Topic: 400

    ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel sensor for the real-time measurement of mitral coaptation force

    SBC: MitralPint Inc.            Topic: NHLBI

    Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of miCas9 mediated gene editing therapies for cystic fibrosis

    SBC: GENETOBE INC            Topic: NHLBI

    Project Summary Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The disease affects multiple organs, with lung disease producing most CF morbidity and mortality. Major progress has been made over the past decade in CF drug development. Greater than 90% patients now benefit from mono or combination therapy of seve ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Multifunctional Rehabilitation Standing and Stepping Device for Persons with Parkinson's Disease

    SBC: TULIP MAKE ME MOVE DESK LLC            Topic: NINDS

    ABSTRACT Tulip Make Me Move Desk, LLC is a startup medical device company based on Randamp;D of the Multifunctional Rehabilitation Standing andamp; Stepping Device (MRSSD) prototype. The MRSSD is a standing desk with a multidirectional moving tabletop that induces stepping movements while standing and simultaneously performing motor and cognitive activities behind it. The MRSSD can serve as a stan ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Troponin Biosensor for Early Detection and Real-time Monitoring of Myocardial Infarction

    SBC: EZ Lab Limited Liability Company            Topic: NHLBI

    Project Summary Cardiovascular disease (CVD) is the leading cause of death for people in most racial and ethnic groups in the United States. Acute Myocardial Infarction (AMI) (also called heart attack) is the top cause of death in CVD. Early detection of AMI translates to earlier intervention and improves survival rates. When cardiac myocytes are damaged, cardiac troponin (cTn), a component of the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid egg bioreactor construction for Fabry disease therapeutics

    SBC: ATGC Inc.            Topic: 300

    AbstractFabry disease is a lysosomal storage disease (LSD) affecting 1 in 40,000 to 117,000 live births. The current treatment is enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (GalA). A major healthcare burden from this treatment is the high drug cost at $350k per patient-year.To reduce the drug cost for Fabry disease, we propose to develop a rapid approach to construc ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government